Literature DB >> 3886827

gp72, the 72 kilodalton glycoprotein, is the membrane acceptor site for C3 on Trypanosoma cruzi epimastigotes.

K Joiner, S Hieny, L V Kirchhoff, A Sher.   

Abstract

We examined the interaction of complement component C3 with surface molecules on Trypanosoma cruzi. Five- to six-fold more C3 was bound to epimastigotes (Epi) than to metacyclic trypomastigotes (CMT) of strain M88. Epi and CMT were surface iodinated, then incubated in C8-deficient serum, and detergent lysates were applied to anti-C3 antibody that had been coupled to Sepharose. We found that 9.20-10.24% of applied 125I-Epi protein bound to anti-C3-sepharose, compared to 2.64% binding of 125I-CMT protein. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed that C3 was attached to 125I-Epi protein by a covalent bond. Samples eluted from anti-C3-sepharose with hydroxylamine revealed a single, major, 72 kD band, suggesting that C3b attaches almost exclusively to the 72 kD glycoprotein of Epi by a hydroxylamine-susceptible ester bond. An antiserum was prepared from lysates of serum-treated Epi that had been affinity-purified on anti-C3-sepharose. This antiserum immunoprecipitated a single 72 kD component (gp72) from surface-iodinated Epi, and specifically recognized only gp72 from Epi in immunoblots. In contrast to the results with Epi, gp72 on CMT was not found to be an efficient acceptor molecule for C3 deposition. The results are the first to evaluate the acceptor site for C3 deposition on a parasite, and they show that gp72 on Epi, but not gp72 on CMT, serves as the preferential acceptor for C3 during antibody-independent alternative complement pathway activation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3886827      PMCID: PMC2187612          DOI: 10.1084/jem.161.5.1196

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  37 in total

1.  Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces.

Authors:  S K Law; N A Lichtenberg; R P Levine
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

2.  Characterization of stages and strains of Trypanosoma cruzi by analysis of cell membrane components.

Authors:  F G Araujo; J S Remington
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

3.  The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.

Authors:  K J Gadd; K B Reid
Journal:  Biochem J       Date:  1981-05-01       Impact factor: 3.857

4.  Purification and regulatory properties of the NADP-linked malic enzyme for Crithidia fasciculata.

Authors:  E Orellano; J J Cazzulo
Journal:  Mol Biochem Parasitol       Date:  1981-05       Impact factor: 1.759

5.  The third component of complement: covalent attachment of a radioactive sugar to the labile binding site of C3 via the alternative pathway.

Authors:  J Mann; R O'Brien; M K Hostetter; C A Alper; F S Rosen; B M Babior
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

6.  Large scale isolation of functionally active components of the human complement system.

Authors:  C H Hammer; G H Wirtz; L Renfer; H D Gresham; B F Tack
Journal:  J Biol Chem       Date:  1981-04-25       Impact factor: 5.157

7.  Evidence for presence of an internal thiolester bond in third component of human complement.

Authors:  B F Tack; R A Harrison; J Janatova; M L Thomas; J W Prahl
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

8.  Enzymatic treatment transforms trypomastigotes of Trypanosoma cruzi into activators of alternative complement pathway and potentiates their uptake by macrophages.

Authors:  T L Kipnis; J R David; C A Alper; A Sher; W D da Silva
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

9.  Trypanosoma cruzi. Surface antigens of blood and culture forms.

Authors:  N Nogueira; S Chaplan; J D Tydings; J Unkeless; Z Cohn
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

10.  The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus.

Authors:  M S Edwards; A Nicholson-Weller; C J Baker; D L Kasper
Journal:  J Exp Med       Date:  1980-05-01       Impact factor: 14.307

View more
  15 in total

1.  Complement component C1q enhances invasion of human mononuclear phagocytes and fibroblasts by Trypanosoma cruzi trypomastigotes.

Authors:  M T Rimoldi; A J Tenner; D A Bobak; K A Joiner
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

2.  Trypanosoma cruzi glycoprotein 72: immunological analysis and cellular localization.

Authors:  G Harth; A A Mills; T Souto-Padrón; W de Souza
Journal:  Mol Cell Biochem       Date:  1992-01-15       Impact factor: 3.396

3.  Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae.

Authors:  K A Joiner; R Scales; K A Warren; M M Frank; P A Rice
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

4.  Mycobacterial protein HbhA binds human complement component C3.

Authors:  S L Mueller-Ortiz; A R Wanger; S J Norris
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

5.  Inefficient complement system clearance of Trypanosoma cruzi metacyclic trypomastigotes enables resistant strains to invade eukaryotic cells.

Authors:  Igor Cestari; Marcel I Ramirez
Journal:  PLoS One       Date:  2010-03-16       Impact factor: 3.240

Review 6.  Infectious diseases associated with complement deficiencies.

Authors:  J E Figueroa; P Densen
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

7.  Developmentally regulated expression by Trypanosoma cruzi of molecules that accelerate the decay of complement C3 convertases.

Authors:  M T Rimoldi; A Sher; S Heiny; A Lituchy; C H Hammer; K Joiner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

Review 8.  Chagas' disease.

Authors:  H B Tanowitz; L V Kirchhoff; D Simon; S A Morris; L M Weiss; M Wittner
Journal:  Clin Microbiol Rev       Date:  1992-10       Impact factor: 26.132

9.  gp 58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from damage by the human alternative complement pathway.

Authors:  E Fischer; M A Ouaissi; P Velge; J Cornette; M D Kazatchkine
Journal:  Immunology       Date:  1988-10       Impact factor: 7.397

10.  Evasion of alternative complement pathway by Trypanosoma cruzi results from inefficient binding of factor B.

Authors:  K Joiner; A Sher; T Gaither; C Hammer
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.